Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.30 |
| ▸ | CHRNA1 | P02708 | 3/20 | 0.30 |
| ▸ | CHRNG | P07510 | 3/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.30 |
| ▸ | CHRND | Q07001 | 3/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27381972 | 1.00 | KDM1A (0.38) | KDM1AMAOBADH1BADH1ACA12 | |
| SCHEMBL17458 | 1.00 | — | — | |
| SCHEMBL665282 | 1.00 | KDM1A (0.38) | KDM1AMAOBADH1BADH1ACA12 | |
| SCHEMBL530404 | 1.00 | KDM1A (0.38) | KDM1AMAOBADH1BADH1ACA12 | |
| Hydrochloric Acid SCHEMBL932936 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL8648521 | 0.96 | KDM1A (0.37) | KDM1AMAOBADH1BADH1ACA12 | |
| Methane SCHEMBL27788609 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL8648518 | 0.96 | KDM1A (0.37) | KDM1AMAOBADH1BADH1ACA12 | |
| Hydrochloric Acid SCHEMBL8308713 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL4166670 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915989-B1 | JAK INHIBITOR AND PREPARATION METHOD THEREFOR | FELICAMED BIOTECHNOLOGY CO LTD (CN) | 2023-06-28 | — | — | EP | disclosed |
| EP-3574922-A1 | MODIFIED OR POLYMER-CONJUGATED FUMAGILLOL METAP2 INHIBITORS FOR USE IN IMPROVING OR RESTORING INSULIN SENSITIVITY | Syndevrx, Inc. (US) | 2019-12-04 | — | — | EP | disclosed |
| US-20170326135-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9757373-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9750737-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | SYNDEVRX, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20160346244-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9433600-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-20150374657-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2015-12-31 | — | — | US | disclosed |
| US-9173956-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140308235-A1 | METAP2 Inhibitors and Methods of Treating Obesity | SYNDEVRX, INC. | 2014-10-16 | — | — | US | disclosed |
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-4140860-A | BACTERICIDES | STERLING DRUG INC. (US) | 1979-02-20 | — | — | US | disclosed |
| US-4119668-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1978-10-10 | — | — | US | disclosed |
| US-4085144-A | ANTIBACTERIAL | STERLING DRUG INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4022833-A | ANTIBACTERIAL AGENTS | STERLING DRUG INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140308235-A1 | METAP2 Inhibitors and Methods of Treating Obesity | METAP2, ADIPOR2, METAP1 | KDM1A 2667/4885MAOB 2782/4885ADH1B 3311/4885 |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | KDM1A 2667/4885MAOB 2782/4885ADH1B 3311/4885 |
| US-20170326135-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | KDM1A 2667/4885MAOB 2782/4885ADH1B 3311/4885 |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | KDM1A 1237/4885MAOB 110/4885ADH1B 1114/4885 |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | PCK2, GOT2, PC | KDM1A 2942/4885MAOB 3756/4885ADH1B 965/4885 |
| US-20160346244-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | KDM1A 2667/4885MAOB 2782/4885ADH1B 3311/4885 |
| US-20150374657-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | KDM1A 2667/4885MAOB 2782/4885ADH1B 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.